DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-071/S-008

GlaxoSmithKline
Attention: Sharon Shapowal, R.Ph.
Director, Avandia, USRA
One Franklin Plaza; P.O. Box 7929
Philadelphia, PA 19101

Dear Ms. Shapowal:

Please refer to your supplemental new drug application dated June 7, 2002, received June 7, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Avandia® (rosiglitazone maleate) Tablets, 2 mg, 4 mg, and 8 mg.

This "Changes Being Effected" supplemental new drug application proposes to revise the **PRECAUTIONS** section, **Weight Gain** subsection of the package insert, to add the following paragraph:

> "In postmarketing experience, there have been rare reports of unusually rapid increases in weight and increases in excess of that generally observed in clinical trials. Patients who experience such increases should be assessed for fluid accumulation and volume-related events such as excessive edema and congestive heart failure."

We completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the labeling text.

The final printed labeling (FPL) must be identical to the labeling submitted on June 7, 2002.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 21-071/S-008." Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Ms. Jena Weber, Regulatory Project Manager, at 301-827-6422.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff

12/3/02 05:54:02 PM